CSTL Q2 2023 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

Q2 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$50M+43.9% YoY

Gross Profit

$39M77.9% margin

Operating Income

-$21M-42.2% margin

Net Income

-$19M-37.5% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

+19.3%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$8M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$425M

Total Liabilities

$47M

Stockholders' Equity

$379M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$35M	+43.9%
Gross Profit	$39M	$27M	+43.9%
Operating Income	-$21M	-$24M	+13.2%
Net Income	-$19M	-$2M	-1039.4%

Revenue Segments

Dermatologic

$43M100%